Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
TerraVolt Holdings, Inc. reported a net loss of $3.9 million for the nine months ended September 30, 2026, compared to a $5.7 million loss in the prior year period. The company is currently pre-revenue and focused on financing and constructing proposed data center operations, with total assets increasing to $13.55 million primarily due to new restricted cash and other assets.
Jasper Therapeutics reported financial results for the third quarter ended September 30, 2026, and provided a corporate update following its acquisition of Kira Pharmaceuticals. The company highlighted progress in its Phase 2 renal basket study for vensobafusp alfa (KP104), including completed enrollment in the IgA nephropathy cohort and the dosing of the first patient with IC-MPGN.
“We have made progress advancing our development programs in recent months following our acquisition of Kira Pharmaceuticals, highlighted by the recent completion of enrollment in the first cohort of our Phase 2 renal basket study evaluating vensobafusp alfa (KP104) in patients with IgA nephropathy (IgAN).”
Jeet Mahal, President and Chief Executive Officer of Jasper
“We believe that the bifunctional ability of vensobafusp alfa to inhibit both the alternative and terminal complement pathways may provide the potential for differentiated onset and efficacy in complement driven diseases, and we look forward to presenting interim data from the IgAN cohort in the fourth quarter of 2026 and additional updates from our pipeline programs in 2027.”
Jeet Mahal, President and Chief Executive Officer of Jasper
Venu Holding Corp reported its Q3 2026 financial results, highlighting a 59% increase in total assets to $587.6 million since year-end 2025. The company is transitioning from a construction phase to an operational phase with the upcoming opening of the Regent Bank Amphitheater on New Year's Eve and the Sunset Amphitheater McKinney in Q1 2027.
Term
Q3 2026
“Next quarter, VENU moves from building to operating. With two venues coming online, we expect to see a meaningful step up in ticketing, food and beverage, and sponsorship revenue in fiscal 2027. Content drives all of it, and we already have more than 110 holds on the calendar across our portfolio.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
“What you see in our results today is the cost of bringing more than $600 million in assets online by mid-2027, and we continue to expect to be in a position to provide financial guidance in the middle of next year.”
J.W. Roth, Founder, Chairman, and Chief Executive Officer
Outdoor Holding Company reported its fiscal second quarter 2027 results, featuring a 14.6% revenue increase to $13.7 million and net income growth to $2.3 million. The company outperformed the broader firearms market with a 10.3% increase in Gross Merchandise Value (GMV) and a 25 basis point increase in take rate to 6.59%.
LanzaTech Global, Inc. reported total revenues of $30.5 million for the nine months ended September 30, 2026, compared to $27.8 million in the prior year period. The company significantly reduced its research and development expenses from $41.7 million to $10.8 million year-over-year, contributing to a narrowed accumulated deficit. However, the filing includes a cautionary note regarding the company's ability to continue as a going concern and its need for additional financing.
Galectin Therapeutics reported financial results for the quarter ended September 30, 2026, and provided a business update on its Phase 3 clinical trial protocol for belapectin in MASH cirrhosis. The company reached alignment with the FDA on the Phase 3 trial design and presented positive new analyses from its NAVIGATE trial at the AASLD Annual Meeting.
Term
3 months
“New analyses were presented at AASLD, marking the fourth consecutive major liver conference where Galectin data was included in an oral presentation. We were extremely pleased by the positive feedback received on the oral presentation as well as the two poster presentations and are excited that our data was included in the AASLD conference highlights and the portal hypertension debrief.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
“As previously disclosed, we submitted our registrational Phase 3 protocol to FDA in the third quarter after reaching alignment on primary elements of the planned Phase 3 trial design. Additional information is expected to be presented at the Annual Stockholders’ Meeting on December 3, 2026.”
Joel Lewis, Chief Executive Officer and President of Galectin Therapeutics
LanzaTech Global reported Q3 2026 revenue of $9.5 million and a net loss of $178.0 million, which was primarily driven by a $166.4 million non-cash unrealized fair value loss on its investment in SGLT. The company highlighted significant cost reductions, with operating expenses down 35% year-over-year, and achieved the world's first ISCC EU certification for recycled carbon fuels from steel mill waste gases.
Term
Q3 2026
“Our third quarter results show continued improvement in our financial and operating performance, building on the progress we have made throughout 2026. The actions we took to reshape LanzaTech are now showing up in our results quarter after quarter; we have held quarterly operating expenses steady for multiple quarters, which tells us the lower cost base we built is durable and sustainable. Our cost structure is now reset for where we are headed operationally and strategically, and LanzaTech now has a much improved position upon which to advance its platform toward commercialization and long-term profitability.”
Dr. Jennifer Holmgren, CEO of LanzaTech
“We are building a business that can monetize waste carbon across multiple end markets rather than depend on a single route to market. This quarter, Hebei Shoulang, a commercial facility using LanzaTech technology, achieved the world’s first ISCC EU Recycled Carbon Fuel certification for ethanol made from steel mill waste gases. This creates a near-term pathway into European road and marine fuel markets, and we have begun commercial discussions with major energy and chemicals companies to convert certification into revenue.”
Galectin Therapeutics reported a net loss of $17.7 million for the nine months ended September 30, 2026, an improvement from the $25.3 million loss in the prior year period. A significant balance sheet event occurred with the conversion of $105.2 million in debt into common stock, substantially reducing total liabilities and increasing the common shares outstanding to over 100 million.
Tyson Foods reported 2026 sales of $56.4 billion, a 3.6% increase driven by higher average sales prices and an additional fiscal week. Despite sales growth, net income attributable to Tyson decreased slightly to $453 million, impacted by significant restructuring charges, legal contingency accruals, and continued operating losses in the Beef segment.
Montauk Renewables reported Q3 2026 revenues of $50.2 million, a 10.9% increase year-over-year, though net income fell 58.9% to $2.1 million. The company announced it has executed a non-binding term sheet to amend its credit facility to borrow additional debt and address liquidity concerns, avoiding a previously anticipated going concern qualification. Additionally, the company plans to invest $15.0 million in enhancements at its Turkey, North Carolina facility to address feedstock moisture and syngas temperature issues limiting commercial production.
Creative Realities reported Q3 2026 revenue of $26.2 million, a significant increase from $10.5 million in the prior-year period, driven by the acquisition of Cineplex Digital Media and new contract wins. The company reported Adjusted EBITDA of $2.7 million and annualized recurring revenue (ARR) of $21.7 million. Management expects full-year 2026 revenue to exceed $100 million, supported by retail media deployments and stadium installations.
Term
Q3 2026
“We continue to set new records this year in terms of growth acceleration, business wins, and EBITDA expansion. We anticipate revenue exceeding $100 million in fiscal 2026, as the fourth quarter is expected to benefit from seasonal factors related to our retail media contracts as well as from the positive impact of recent awards and new customer installations.”
Rick Mills, Chief Executive Officer
“We focused on the balance sheet this quarter, using existing cash to pay down debt, provide increased financial flexibility, and reduce ongoing interest expense. Our talented staff and leadership successfully executed an operating strategy that is producing significant growth as we become a more nimble organization intent on achieving improved bottom line results and cash generation.”
Tyson Foods reported fourth quarter and fiscal year 2026 results, with annual sales increasing 3.6% to $56.4 billion. While GAAP operating income remained flat at $1.1 billion, adjusted EPS for the full year declined 17% to $3.44, reflecting a challenging operating environment despite growth in Prepared Foods and resilience in the Chicken segment.
“Our performance in fiscal 2026 reflects the strength of our diversified multiprotein model and our dedication to our customers and consumers. We’ll build on those strengths through investment in our brands, innovation and operating capabilities, while remaining focused on the returns those investments can deliver alongside market conditions.”
Jeff Schomburger, President and CEO of Tyson Foods
Edible Garden reported third quarter 2026 financial results, featuring a 14% revenue increase to $3.2 million and a significant gross margin expansion to 23.9%. The company highlighted strong growth in cut herb sales and secured a major private-label RTD protein beverage award from a large grocery retailer. Management noted that these improvements were achieved during the company's seasonally slowest quarter.
Term
Q3 2026
“Our third-quarter results reflect meaningful progress in strengthening our business.”
Jim Kras, Chief Executive Officer of Edible Garden
VIDA Global reported Q3 2026 financial results with revenue increasing 88% year-over-year to $0.33 million. The company highlighted the transition of its computer agents out of beta and the expansion of its go-to-market team and partnerships with ALLO Fiber and AVANT.
Term
Q3 2026
“In the third quarter, we believe we put the foundation in place to scale Vida’s AI workforce. Our computer agents came out of beta, so Vida’s AI employees now have the ability to do the work behind the conversation, not just the conversation. We built outcome-based billing, expanded our sales team, and signed partners including ALLO Fiber and AVANT.”
Agape ATP Corp reported a significant decline in revenue to $40,079 for the nine months ended September 30, 2026, compared to $352,844 in the prior year. Despite the revenue drop, the net loss narrowed to $275,153 from $1,931,535, primarily due to a substantial $1.3 million foreign exchange gain and income from the disposal of discontinued operations.
ZW Data Action Technologies Inc. reported total assets of $10.68 million as of September 30, 2026, an increase from $9.68 million at the end of 2025. The company continues to navigate regulatory risks associated with the Holding Foreign Companies Accountable Act (HFCAA) due to its auditor's location in Hong Kong.
MapLight Therapeutics reported a significant increase in net loss to $172.5 million for the nine months ended September 30, 2026, compared to $81.6 million in the prior year, primarily driven by a doubling of research and development expenses. The company strengthened its balance sheet through a private placement in the third quarter of 2026, yielding $140.1 million in net proceeds.
CNS Pharmaceuticals reported a net loss of $10.0 million for the nine months ended September 30, 2026, while significantly strengthening its cash position to $17.2 million following a $22.5 million private placement in May 2026. The company is currently pivoting its corporate strategy toward acquiring new therapeutic assets and exploring out-licensing opportunities for its legacy glioblastoma programs.
FitLife Brands reported a 39.5% increase in revenue for the nine months ended September 30, 2026, reaching $77.5 million compared to $55.5 million in the prior year. Net income for the nine-month period rose to $5.24 million, driven by organic growth and the impact of the Irwin acquisition, despite higher interest expenses and selling costs.
Moleculin Biotech reported Q3 2026 financial results and announced the completion of treatment for all 90 patients in Part A of its pivotal Phase 2/3 MIRACLE trial for Annamycin in AML. The company remains on track for a comprehensive data readout in Q1 2027, which will inform dose selection for the planned initiation of Part B in the first half of 2027.
“We are approaching one of the most important milestones in Moleculin's development, and I believe our progress has positioned us to enter 2027 with meaningful momentum. Completing treatment of all 90 patients in Part A of our pivotal MIRACLE trial is a significant execution achievement.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
“We have reported encouraging interim clinical findings, strengthened the scientific foundation supporting Annamycin's differentiated cardiac safety profile through independent, peer-reviewed analysis, and continued to execute against our pivotal development strategy.”
Walter Klemp, Chairman and Chief Executive Officer of Moleculin
Prelude Therapeutics reported a net loss of $36.9 million for the nine months ended September 30, 2026, a significant improvement from the $83.0 million loss in the prior year period, driven by a decrease in R&D expenses and $15.9 million in recognized revenue. The company strengthened its balance sheet through a $90.0 million issuance of common stock and pre-funded warrants, ending the period with $142.4 million in total current assets.
MapLight Therapeutics reported Q3 2026 financial results and provided a clinical pipeline update, including plans for its Phase 3 ZEPHYR-2 trial in schizophrenia. The company ended the quarter with $463.4 million in cash, which is expected to fund operations through 2028 and key clinical readouts.
Term
Q3 2026
“Following the positive results from our ZEPHYR study, we are focused on advancing ML-007C-MA into an additional registrational study and positioning it to compete in the broader antipsychotic market.”
Chris Kroeger, Co-Founder and Chief Executive Officer
“We believe that the strength and consistency of the ZEPHYR efficacy results, combined with the ease-of-use tolerability profile, provide a solid foundation for our planned Phase 3 trial and reinforce our confidence in the potential of ML-007C-MA in schizophrenia.”
Chris Kroeger, Co-Founder and Chief Executive Officer
Xtend AI Robotics reported Q3 2026 revenue of $14.9 million, a 281% year-over-year increase, driven by its AI Robotics segment. The company ended the quarter with a fully funded backlog exceeding $100 million and $66.7 million in cash following its NYSE listing and business combination with JFB Construction.
Term
Q3 2026
“Our first quarter as a public company shows our strategy is working. Revenue nearly quadrupled, nine-month revenue has already passed all of 2025, and we ended the quarter with a fully funded backlog of more than $100 million. XTEND is not just another drone company. We are a Physical AI company”
Aviv Shapira, Co-Founder and Chief Executive Officer
Larimar Therapeutics reported third quarter 2026 financial results and announced the completion of its rolling BLA submission to the FDA for nomlabofusp in Friedreich’s ataxia. The company ended the quarter with $128.7 million in cash, providing a projected runway into late Q2 2027 as it prepares for a potential U.S. launch in Q3 2027.
“Completing the BLA submission for nomlabofusp marks a major milestone for Larimar and the Friedreich’s ataxia (FA) community. The next 12 months are expected to bring several pivotal registrational catalysts, including FDA review of our application and progression of FORWARD-FA, our global confirmatory Phase 3 study.”
Carole Ben-Maimon, M.D., Chief Executive Officer
“In parallel, we are preparing for a potential U.S. launch in the third quarter of 2027, if approved, while evaluating options to support global commercialization.”
Instil Bio, Inc. reported a net loss of $13.0 million for the nine months ended September 30, 2026, a significant reduction from the $63.5 million loss in the prior year period. The company is transitioning its strategy, having discontinued its lead product candidate AXN-2510 in January 2026, and is currently seeking to in-license or acquire new therapeutic candidates.
Sativus Tech Corp. reported a net loss of $539 thousand for the nine months ended September 30, 2026, compared to $923 thousand in the prior year. The company faces substantial doubt about its ability to continue as a going concern due to an accumulated deficit of $24.9 million and negative operating cash flows.
Venu Holding Corp reported total revenues of $14.09 million for the nine months ended September 30, 2026, a slight increase from $13.37 million in the prior year. The company experienced a significant net loss of $49.81 million during this period, driven by high general and administrative expenses and equity-based compensation. Total assets grew to $587.63 million, primarily due to a substantial increase in property and equipment related to amphitheater development.
Xtant Medical Holdings reported total assets of $75.2 million as of September 30, 2026, a decrease from $94.1 million at year-end 2025, primarily driven by a reduction in cash and the settlement of a $10.5 million note receivable. The company is currently undergoing a strategic review by its Board of Directors and recently expanded its product portfolio with the exclusive distribution of HEMOBLAST Bellows.
QVC Group, Inc. has emerged from Chapter 11 bankruptcy proceedings as of July 20, 2026, implementing a reorganization plan that includes approximately $1.3 billion in Takeback Debt and a $600 million Exit ABL Facility. The company reported 49,999,897 shares of common stock outstanding as of October 31, 2026, and is now operating under fresh start accounting which limits comparability to historical financial periods.
Barrel Energy Inc. reported a significant net loss of $1,518,216 for the nine months ended September 30, 2026, compared to a net income of $53,795 in the prior year period. The loss was primarily driven by a $1,056,653 change in the fair value of derivative liabilities and a substantial increase in operating expenses including consulting, marketing, and R&D.